Jaing T-H, Wang Y-L. Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”. Haematologica [Internet]. 2026Sep.17 [cited 2026Nov.5];. Available from: https://haematologica.org/article/view/14432